Abstract:
The process of dead cell clearance by phagocytic cells, called efferocytosis, prevents inflammatory cell necrosis and promotes resolution and repair. Defective efferocytosis contributes to the progression of numerous diseases in which cell death is prominent, including liver disease. Many gaps remain in our understanding of how hepatic macrophages carry out efferocytosis and how this process goes awry in various types of liver diseases. Thus far, studies have suggested that, upon liver injury, liver-resident Kupffer cells and infiltrating monocyte-derived macrophages clear dead cells, limit inflammation, and, through macrophage reprogramming, repair liver damage. However, in unusual settings, efferocytosis can promote liver disease. In this review, we will focus on efferocytosis in various types of acute and chronic liver diseases, including metabolic dysfunction-associated steatohepatitis. Understanding the mechanisms and consequences of efferocytosis by hepatic macrophages has the potential to shed new light on liver disease pathophysiology and to guide new treatment strategies to prevent disease progression.
摘要:
吞噬细胞清除死细胞的过程,叫做红细胞增多症,防止炎症细胞坏死,促进分辨率和修复。有缺陷的红细胞增多有助于许多细胞死亡突出的疾病的进展,包括肝脏疾病。在我们对肝巨噬细胞如何进行有效增殖以及该过程在各种类型的肝脏疾病中如何出错的理解中仍然存在许多差距。到目前为止,研究表明,肝损伤后,肝脏驻留的Kupffer细胞和浸润的单核细胞衍生的巨噬细胞清除死细胞,限制炎症,and,通过巨噬细胞重编程,修复肝脏损伤。然而,在不寻常的环境中,红细胞增多可以促进肝脏疾病。在这次审查中,我们将专注于各种类型的急性和慢性肝病的红细胞增多症,包括代谢功能障碍相关的脂肪性肝炎。了解肝巨噬细胞有效增殖的机制和后果有可能为肝病病理生理学提供新的启示,并指导新的治疗策略以预防疾病进展。